Drugs / CHS-388
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04374877 | Apr 2020 → May 2025 | clear cell renal carcinoma, hepatocellular carcinoma, non-small cell lung carcinoma | Coherus Oncology, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CHS-388 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04374877 ↗ |
| Action | Inhibit | “Inhibition of IL-27 with CHS-388 reduces STAT1 phosphorylation” NCT04374877 ↗ |